Skip to main content
JIUZHITANG CO.,LTD logo

JIUZHITANG CO.,LTD — Investor Relations & Filings

Ticker · 000989 ISIN · CNE000001394 LEI · 3003004OFW6FCZ34KN72 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,885 across all filing types
Latest filing 2024-11-12 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 000989

About JIUZHITANG CO.,LTD

https://www.hnjzt.com

JIUZHITANG CO.,LTD. is a pharmaceutical enterprise specializing in the research, development, manufacturing, and distribution of Traditional Chinese Medicine (TCM). Established in 1650, the company is recognized as a time-honored brand with a heritage spanning over three centuries. Its core product portfolio includes a diverse range of TCM formulations, most notably Liuwei Dihuang Wan, donkey-hide gelatin (Ejiao), and various health supplements focused on chronic disease management and general wellness. The company operates modern production facilities that integrate traditional processing techniques with contemporary scientific standards and biotechnology. JIUZHITANG focuses on the modernization of TCM through clinical research and innovation, maintaining a distribution network that serves retail pharmacies and medical institutions to provide natural healthcare solutions.

Recent filings

Filing Released Lang Actions
九芝堂股份有限公司详式权益变动报告书（辰能创投）
Major Shareholding Notification Classification · 95% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report". It is issued by a shareholder (黑龙江辰能工大创业投资有限公司) regarding an increase in its equity stake in 九芝堂股份有限公司, a listed company on the Shenzhen Stock Exchange. The document details the nature of the equity change, the share transfer agreement, the parties involved, the shareholding percentages before and after the transaction, the funding source, and future plans related to the shareholding. It references relevant laws and regulations such as the Company Law, Securities Law, and specific disclosure standards (准则第15号 and 准则第16号) related to equity changes and takeover reports. The content is comprehensive and includes financial data, legal compliance statements, and procedural details about the share transfer. This type of document corresponds to a Major Shareholding Notification (MRQ), which involves notifying the market and regulators about significant changes in share ownership levels, especially crossing thresholds that affect control or influence over the company. It is not an announcement of a report publication, nor a full annual or interim report, nor a proxy or voting result announcement. Therefore, the correct classification is MRQ with high confidence.
2024-11-12 Chinese
九芝堂股份有限公司简式权益变动报告书（李振国）
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of a significant shareholder (李振国) in 九芝堂股份有限公司, including the nature of the equity change, share quantities before and after, the agreement for share transfer, and related legal and procedural details. It references relevant securities laws and disclosure standards for equity changes. The document is comprehensive and contains detailed information about the shareholding change, the parties involved, and the transaction terms. This matches the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report publication, nor is it a financial report or management report. It is a regulatory disclosure specific to shareholding changes.
2024-11-11 Chinese
关于控股股东协议转让股权暨控制权拟发生变更和权益变动的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a significant equity transfer involving the controlling shareholder and actual controller of the company 九芝堂股份有限公司. It includes specifics about the share transfer agreement, changes in control, shareholding percentages before and after the transaction, conditions precedent, governance implications, and compliance with relevant laws and regulations. The document does not contain financial statements or quarterly/annual financial results but focuses on the change in control and shareholding structure. This fits the definition of a Capital/Financing Update (CAP), as it relates to changes in ownership and control through share transfer agreements and equity transactions. The document length and detail confirm it is not a brief announcement or a simple notice but a substantive update on capital structure and control changes.
2024-11-11 Chinese
关于参股公司研发新药在国内启动临床试验的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about a clinical trial approval for a new drug developed by an affiliated company. It details the drug's name, clinical trial purpose, regulatory approval status, and risk warnings. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about a clinical trial initiation, not a financial report or management report. It is also not a voting result, capital update, or legal proceeding. Given the content and length (1657 characters), it fits best as a Regulatory Filing (RNS) since it is a formal disclosure of material information to investors and regulators without financial data or report attachments.
2024-11-01 Chinese
关于股份回购进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase (stock buyback) program by 九芝堂股份有限公司. It details the approved repurchase plan, the amount and price limits, the progress of shares repurchased up to a certain date, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial analysis but focuses on the status and regulatory compliance of the share repurchase activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-11-01 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第三季度报告" which translates to "2024 Third Quarter Report." It contains detailed financial data including revenue, net profit, cash flow, earnings per share, and changes in assets and liabilities for the third quarter period. It also includes shareholder information and detailed financial metrics. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year (third quarter) clearly indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2024
2024-10-29 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.